ClinicalTrials.gg
CompletedNCT04930809Updated Jul 14, 2022

Single and Multiple Dose Study of VER-01 in Healthy Volunteers

A Phase 1 interventional study of VER-01 in Healthy, sponsored by Vertanical GmbH. Completed at 1 site in Austria. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-14.

Sponsored by Vertanical GmbH · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

Evaluation of pharmacokinetics, tolerability and safety of VER-01 in healthy volunteers

Read the detailed description

Determination of the single and multiple dose pharmacokinetic profile of VER-01 in healthy volunteers.

Single dose: 6 subjects each will receive VER-01 corresponding to 2.5 mg (Group A), 5 mg (Group B), 10 mg (Group C) or 20 mg THC (Group D) in the morning.

Multiple dose: 6 Subjects each receive VER-01 corresponding to 5 mg (Group E) or 10 mg (Group F) THC in the morning and in the evening on 4 consecutive days. A third group (Group G) receives VER-01 corresponding to 12.5 mg THC in the morning and 20 mg THC in the evening on 4 consecutive days.

02

Conditions studied

  • Healthy

Keywords

  • THC
  • Tetrahydrocannabinol
  • Cannabis
  • Pharmacokinetics
03

In context

Lead sponsor

Vertanical GmbH is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male volunteers
  • Age: 18-45 years
  • : 19-30 kg/m²
  • Body weight ≥ 50 kg
  • volunteers in good general condition based on medical history, physical examination, resting and clinical laboratory tests
  • Willingness of men to use a reliable method of and not to donate sperm during and at least 3 months after the last intake of the study product
  • Understanding of the German language, ability to give consent and compliance
  • The subject has understood the instructions to avoid changes in lifestyle and eating habits
  • Signed patient information and written form of the study participant

Exclusion criteria

Exclusion Criteria:

  • Consumption of cannabis-based products within 30 days prior to study start
  • Well-known strong adverse events in connection with cannabis consumption
  • Known allergy to cannabis, sesame seeds, or derivative products
  • alcohol/drug/medication abuse or physical dependence on opioids, barbiturates, amphetamines, cocaine or benzodiazepines within the last 10 years or current intake of methadone
  • Positive drug test for illegal substances and/or alcohol test at time T0
  • Heavy smokers (>10 cigarettes/day)
  • Heavy caffeine consumers (>450 mg caffeine/day equal to approx. 5-6 cups of filter coffee)
  • Drastic change in diet within 30 days before study start
  • Mental illness (psychoses, schizophrenia, bipolar disorder, severe depression, anxiety disorder, suicide)
  • Mental illness (psychoses, schizophrenia, bipolar disorder, severe depression, anxiety disorder, suicide) in a first-degree relative (parents and children)
  • subjects with orthostatic hypotension during screening (drop in systolic blood pressure by ≥20 mmHg after change of position)
  • Cardiovascular event within the last 3 months, untreated hypertension, untreated hypothyroidism, surgery within the last 2 months
  • cardiac insufficiency
  • Subjects with a serious disease or disorder which, in the opinion of the investigator, does not allow safe participation in the study from a medical point of view
  • Intake of prescription drugs within the last 14 days, over-the-counter test products within the last 7 days before the start of the study or during the study period
  • Eating of grapefruit products is not allowed during the study and 10 days before the first intake of the study product
  • Participation in another clinical trial in the period of 90 days before the start of the trial
  • Existing desire to have children or planned sperm donation (within the duration of the study and 3 months after end of the study)
  • Planned blood donation
  • No ability to consent
  • Subject is in a dependency/employment relationship with the sponsor or investigator or other persons who may be under pressure.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    VER-01 single dose (2.5 mg THC)

    PK profile is investigated after oral intake of a single dose VER-01 corresponding to 2.5 mg THC (Group A).

    Drug: VER-01

  • Experimental
    VER-01 single dose (5 mg THC)

    PK profile is investigated after oral intake of a single dose VER-01 corresponding to 5 mg THC (Group B).

    Drug: VER-01

  • Experimental
    VER-01 single dose (10 mg THC)

    PK profile is investigated after oral intake of a single dose VER-01 corresponding to 10 mg THC (Group C).

    Drug: VER-01

  • Experimental
    VER-01 single dose (20 mg THC)

    PK profile is investigated after oral intake of a single dose VER-01 corresponding to 20 mg THC (Group D).

    Drug: VER-01

  • Experimental
    VER-01 multiple dose (5 mg THC)

    PK profile is investigated after oral intake of VER-01 corresponding to 5 mg THC in the morning and 5 mg THC in the evening on 4 consecutive days (Group E).

    Drug: VER-01

  • Experimental
    VER-01 multiple dose (10 mg THC)

    PK profile is investigated after oral intake of VER-01 corresponding to 10 mg THC in the morning and 10 mg THC in the evening on 4 consecutive days (Group F).

    Drug: VER-01

  • Experimental
    VER-01 multiple dose (12.5 / 20 mg THC)

    PK profile is investigated after oral intake of VER-01 corresponding to 12.5 mg THC in the morning and 20.5 mg THC in the evening on 4 consecutive days (Group F).

    Drug: VER-01

Interventions

  • DrugVER-01

    standardised cannabis extract (containing 21 mg THC per gram drug product)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-t

    Analysis of the AUC 0-t (AUC from time 0 to 24 hours) of THC over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  2. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - AUC 0-∞

    Analysis of AUC 0-∞ (AUC from time 0 extrapolated to infinity) of THC over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  3. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC] - C max

    Analysis of C max (maximum plasma concentration) of THC over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

Secondary outcomes

  1. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - AUC 0-t

    Analysis of AUC 0-t (AUC from time 0 to 24 hours) of 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  2. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - AUC 0-∞

    Analysis of AUC 0-∞ (AUC from time 0 extrapolated to infinity) of 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  3. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - C max

    Analysis of C max (maximum plasma concentration) of 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  4. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - λ z

    Analysis of λ z (terminal elimination constant) of THC, 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  5. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - t 1/2

    Analysis of t 1/2 (elimination half-life) of THC, 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  6. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - T max

    Analysis of T max (time to reach Cmax) of THC, 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  7. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - C L/F

    Analysis of C L/F (plasma clearance) the pharmacokinetic profile of THC, 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

  8. Pharmacokinetic profile of Δ9-tetrahydrocannabinol [THC], 11-Hydroxy-Δ9-tetrahydrocannabinol [11-OH-THC] and 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol [THC-COOH] - V area/F

    Analysis of V area/F (volume of distribution) of THC, 11-OH-THC and THC-COOH over a defined period of time.

    Time frame: Group A-D: Day 1; Group E-G: Day 1 and 4

07

Study locations

1 site
  • University of Medicine in Vienna - Department of Clinical Pharmacology
    Vienna, 1090, Austria
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jul 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2021
First posted
Jun 18, 2021
StartActual
Nov 25, 2021
Primary completionActual
Jul 4, 2022
CompletionActual
Jul 11, 2022
Last update
Jul 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04930809
Lead sponsor
Vertanical GmbH
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Nov 25, 2021
Primary completion
Jul 4, 2022
Completion
Jul 11, 2022
Last update
Jul 14, 2022

Study contacts

Michael Wolzt, Professor
principal investigator · University of Medicine in Vienna - Department of Clinical Pharmacology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VER-01

Start the discussion